ライフサイエンスコーパス: chelator

1 inhibitors as a pharmacophore rather than a "chelator".

2 f dissolved glutathione (a thiolate-based Hg chelator).

3 city using diets supplemented with a calcium chelator.

4 d amounts of either the metal complex or the chelator.

5 he chemical property of vancomycin as a zinc chelator.

6 abeled with (177)Lu through the CHX-A''-DTPA chelator.

7 uproine disulfonate, a cell-impermeant Cu(I) chelator.

8 y employing a wide variety of supramolecular chelators.

9 tion when combined with clinically available chelators.

10 of sodium chloride with or without the metal chelators.

11 imulation and in vitro by exposure to Ca(2+) chelators.

12 s and this effect can be controlled by metal chelators.

13 or the promising anticancer activity of iron chelators.

14 with the activity of potent anticancer iron chelators.

15 ing affinity and selectivity among molecular chelators.

16 portant differences in the behavior of the 4 chelators.

17 copper-only SODs highly vulnerable to metal chelators.

18 tment of cells with the intracellular Ca(2+) chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraac

19 (2+)](i) and secretion was blocked by Ca(2+) chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraac

20 80 kDa) format were functionalized with the chelator 1,4,7-triazacyclononane-1-glutaric acid-4,7-dia

21 tive to addition of zinc acetate or the zinc chelators 1,10-o-phenanthroline and EDTA.

22 s (64)Cu-LLP2A, which is conjugated with the chelator (1,4,8,11-tetraazacyclotetradecane-1-(methane p

23 Furthermore, either the [Ca(2+)]i chelator(1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraac

24 on content using the membrane-permeable iron chelator 2,2'-dipyridyl effectively removes the [2Fe-2S]

25 ibitory concentrations of the synthetic iron chelator 2,2'-dipyridyl.

26 nent system (TCS) and the TCS-regulated iron chelator 2-isocyano-6,7-dihydroxycoumarin (ICDH-Coumarin

27 inding with a non-toxic siderophore-inspired chelator, 2,6-bis[hydroxy(methyl)amino]-4-morpholino-1,3

28 The binding of three closely related chelators: 5-hydroxy-2-methyl-4H-pyran-4-thione (allothi

29 sing desferrithiocin, a natural product iron chelator (a siderophore), as a platform for structure-ac

30 in 55 +/- 12% radiochemical yield through a chelator-accelerated one-pot cycloaddition reaction medi

31 Calcium chelators act similarly and mitochondrially targeted ant

32 II) uptake system utilizing a secreted metal chelator, akin to siderophore-mediated Fe(III) acquisiti

33 Unfortunately, therapeutic iron chelators also have undesired toxicity and may deliver i

34 re characterized, after conjugation to a DFO chelator and (89)Zr radiolabeling, in assays including c

35 H2O)](-) was modified to form a bifunctional chelator and 4 chelates were conjugated to a fibrin-spec

36 lloprotease inhibitors relies on a core zinc chelator and a peptidic or nonpeptidic scaffold that pro

37 o 2' -deoxymugineic acid (DMA), a related Fe chelator and enhancer of Fe bioavailability, and increas

38 affinity using a modified nitrilotriacetate chelator and exhibits an almost 6 order of magnitude dec

39 duced cell viability when combined with a Cu chelator and induced CASPASE-dependent cell death.

40 vesicle (SV) coupling distance using Ca(2+) chelator and inhibitor of septin cytomatrix in morpholog

41 helating agent and the linker moiety between chelator and pharmacophore, which influence the overall

42 AC-10 was conjugated with a DFO B chelator and radiolabeled with (89)Zr to give formulated

43 as evaluated by conjugating A9 with the DTPA chelator and radiolabeling it with (111)In.

44 beta-cyclodextrin (HPbetaCD), a cholesterol chelator and the only promising treatment for NPC1.

45 such as nilotinib, inosine, isradipine, iron chelators and anti-inflammatories, and discuss how their

46 rug sensitivity elicited by combining copper chelators and BH3 mimetics for treatment of BRAF(V600E)

47 Experiments using chelators and imaging both indicated that presynaptic Ca

48 lays impaired growth in the presence of iron chelators and increased production of the virulence fact

49 ions have been performed with water-soluble chelators and indicators that typically require careful

50 onse under normoxic conditions, such as iron chelators and inhibitors of prolyl hydroxylase domain (P

51 Both iron chelators and LXR agonists improve the response of P47S

52 roved management of iron overload using oral chelators and non-invasive MRI measurements, and point-o

53 vel SPECT radiopharmaceuticals, creating new chelators and prosthetic groups for radiolabeling.

54 53 expression, which was abrogated by Ca(2+) chelators and short hairpin RNA-mediated knockdown of Cn

55 mice for 26 weeks with deferiprone (an iron chelator) and report that it reversed their skin photose

56 des were synthesized, conjugated to a copper chelator, and radiolabeled with (64)Cu.

57 y addition of a slight excess of a palladium chelator, and the interaction can be reversibly switched

58 ent cell death (ferroptosis) as well as iron chelators, and thus creates a metabolic vulnerability th

59 model is more suitable for SOSDEs with metal chelator antioxidants e.g. EDTA, than free radical scave

60 lkiness of the residues at the tetramic acid chelator are decisive for the stereochemical outcome.

61 One of the most promising classes of iron chelators are alpha-N-heterocyclic thiosemicarbazones wi

62 The experimental methods by which chelators are assessed for their suitability with a vari

63 ection of the most common and most promising chelators are evaluated and discussed for their potentia

64 conditions, these high-affinity ferric iron chelators are excreted by bacteria in the soil to acquir

65 Two new iron chelators are in development, one in phase 3 clinical tr

66 diopharmaceuticals bearing bifunctional HBED chelators are powerful radiotracers for cancer diagnosis

67 However, existing copper chelators are too toxic or ineffective for cancer treatm

68 vels, we required a high-affinity rapid zinc chelator as well as an extracellular ratiometric fluores

69 bodies with 2 forms of DOTA as well as other chelators as controls.

70 ighting the potential for repurposing copper chelators as enhancers of antitumor immunity.

71 90 inhibition, we propose CPX and other iron chelators as investigational antitumor agents in NB ther

72 flexible co-targeting, addition of metal ion chelators as models for imaging and radiotherapy, and li

73 ed antagonists, modified with DOTA or NODAGA chelators at positions Lys(27) and Lys(40) and labeled w

74 Conjugation of DOTA and NODAGA chelators at positions Lys(27) and Lys(40) of Ex(9-39)NH

75 lgal host and other bacteria, including iron chelators, B vitamins, methionine, lycopene, squalene an

76 hat dialysing recorded cells with the Ca(2+) chelator BAPTA (10 mM) increased the magnitude of I(NMDA

77 genetic mutations or exposure to the Ca(2+) chelator BAPTA can, however, still respond to mechanical

78 he intracellular concentration of the Ca(2+) chelator BAPTA caused smaller increases in resting open

79 reatment of MDA-MB-231 cells with the Ca(2+) chelator BAPTA or an inhibitor of endoplasmic reticulum

80 in the cells; effects mitigated by [Ca(2+)]i chelator BAPTA, calcineurin/NFAT inhibitor VIVIT, and TR

81 entry, cells were incubated with the calcium chelator BAPTA-AM (1,2-bis(o-aminophenoxy)ethane-N,N,N',

82 The calcium chelator BAPTA-AM, which reduces cytosolic calcium, resc

83 lycaconitine (MLA) and intracellular calcium chelator BAPTA.

84 nase kinase 2 inhibitor (STO-609) or calcium chelator (BAPTA-AM).

85 By contrast, calcium chelator BAPTM/AM and MEK inhibitor (U0126) can reverse

86 Ns should be less toxic than existing copper chelators because they favorably deprive copper in the m

87 transferase) was conjugated to the metal ion chelator benzyl-diethylenetriaminepentaacetic acid to al

88 Using a metal ion chelator beta-thujaplicinol as a molecular probe, we obs

89 escribed herein are a series of bifunctional chelators (BFCs), L1-L5, that were designed to tightly b

90 ns, with particular emphasis on bifunctional chelators (BFCs), which ensure secure consolidation of t

91 The small molecule metal ion chelators bipyridine and terpyridine complexed with Zn(2

92 ogenic microorganisms secrete small molecule chelators called siderophores defined by their ability t

93 host-sequestered iron by high-affinity iron chelators called siderophores.

94 eviously discovered that small-molecule zinc chelators called zinc metallochaperones (ZMCs) reactivat

95 nst CaMKII activation data in the absence of chelators, CaMKII activation dynamics due to synaptic in

96 However, small molecule-based iron chelators can cause adverse side effects such as infecti

97 However, thus far, no bifunctional HBED chelator capable of direct conjugation via click chemist

98 semiessential amino acid and a potent metal chelator, CAT4 orthologs could be considered as candidat

99 We found that BAPTA-based calcium chelators cause immediate depolymerization of spindle mi

100 nown short cyclic peptide to a cross-bridged chelator (CB-TE2A), followed by labeling with copper-64.

101 -phenylbutyrate (4-PBA), as well as the iron chelator ciclopirox (CPX), which reduces ER stress, alle

102 tified that the food-safe and common cadmium chelator citric acid efficiently removed cadmium from in

103 floxacin, and enrofloxacin are powerful iron chelators comparable with deferoxamine, a clinically use

104 overall binding mode of all three metal ion chelator complexes, the pyridine ring of ZnClTerp blocks

105 (227)Th complexed to a 3,2-hydroxypyridinone chelator conjugated to a tumor-targeting monoclonal anti

106 Chelator conjugation was confirmed by electrospray ioniz

107 pi electrons of graphene without the need of chelator conjugation, providing a promising alternative

108 Certain siderophores-bacterial iron chelators-consist of paired catechol and lysine function

109 Here, we found that iron chelators consistently inhibited mTORC1 signaling, which

110 ineffective extracellular hydroxypyridinone chelator, CP40.

111 ne (DFP) is a hydroxypyridinone-derived iron chelator currently in clinical use for iron chelation th

112 Chelex treatment and iron chelators decreased H(2)O(2) generation suggesting that

113 We assessed whether the iron chelator deferiprone can reduce brain iron and slow dise

114 bel" administration of the FDA-approved iron chelator deferiprone evidenced significant reductions in

115 not alter the beneficial effect of the iron chelator deferiprone on iron overload.

116 Treatment of NZB/W mice with the iron chelator deferiprone significantly delayed the onset of

117 deletion, as well as treatment with the iron chelator deferiprone, preserves vision and attenuates re

118 Thus, the iron chelators deferiprone (L1) and deferoxamine (Dfx), which

119 chelation therapy with one of the three iron chelators (deferiprone, deferasirox, or deferoxamine).

120 This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to chelat

121 with HIF-1alpha-stabilizing drugs: the iron chelator deferoxamine (Desferal [DFO]), a neddylation in

122 The iron chelator deferoxamine (DFO) has been shown to improve sk

123 se hippocampal neuron cultures with the iron chelator deferoxamine (DFO) to model chronic energetic i

124 dionuclide zirconium 89 ((89)Zr) through the chelator deferoxamine (DFO), or (89)Zr-DFO-daratumumab,

125 , and reduced following addition of the iron chelator deferoxamine (DFO).

126 xtrahepatic protoporphyria) or with the iron chelator deferoxamine and the porphyrin precursor 5-amin

127 Retro-orbital infusion of PP-IX or the iron chelator deferoxamine mesylate (DFO), with the first com

128 We aimed to assess the safety of the iron chelator deferoxamine mesylate in patients with intracer

129 o H(2)O(2), which was alleviated by the iron chelator deferoxamine.

130 nedioxythiophene) (PEDOT) into which an iron chelator, deferoxamine (DFA), has been doped during the

131 transferrin or the membrane-impermeable iron chelator, deferoxamine mesylate salt, was able to increa

132 ons, Fe(3+), using a gamma-pyrone derivative chelator, demonstrate subpicomolar limit of detection wi

133 induced NOD-dependent signaling, and calcium chelators demonstrated a role for both intracellular and

134 Exposure to the iron chelator desferrioxamine decreased SPH forming efficienc

135 as also demonstrated with the classical iron chelator, desferrioxamine (DFO), and was not observed fo

136 ite-specifically derivatized with the (89)Zr chelator desferroxamine B via a 3.4-kDa PEG linker.

137 glycyl-glycyl-glycyl-cysteine peptide-based chelator (designated ZHER2:V2) has the best biodistribut

138 The selective antitumor and antimetastatic chelator di-2-pyridylketone 4,4-dimethyl-3-thiosemicarba

139 We observed that the chelator, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarb

140 als, by flash photolysis of the caged Ca(2+) chelator diazo-2-acetoxymethyl ester, arrests mitosis.

141 However, pretreatment of mucin with iron chelator DIBI, but not deferoxamine, partially abolished

142 The nickel (Ni)-specific chelator dimethylglyoxime (DMG) has been used for many y

143 s but restored after the addition of an iron chelator dipyridyl.

144 ssing the catalytic activity, with different chelators displaying different deceleration capacities.

145 The chelator DOTA was used in all cases.

146 ced by ascorbate but is a very strong Cu(II) chelator due to residues that interacts with the N-termi

147 ethylenediaminetetraacetic acid (EDTA, metal chelator) during sample preparation could not only incre

148 Metal ion chelating resin, or the chelators EDTA and desferrioxamine decreased monatin and

149 mor cell growth and survival by enhancing Cu chelator efficacy with chemical inducers of apoptosis, e

150 on of high concentrations of the slow Ca(2+)-chelator EGTA, but EGTA had no effect in synaptotagmin-7

151 2+) is depleted by the high-affinity calcium chelator EGTA, suggesting that the calcium present in th

152 atively accounted for in the presence of the chelators EGTA and BAPTA without additional adjustments

153 When combined with these chelators, ELT enhanced cellular iron mobilization more

154 The use of the macropa chelator enabled quantitative radiolabeling and may faci

155 jugation to a maleimido derivative of a DOTA chelator, enabling radionuclide labeling, (1)(1)(1)In fo

156 strongly and systemically, while the Ca(2+) chelator ethylene glycol tetraacetic acid (EGTA) signifi

157 Affinity constants derived for the chelator/Fe(3+) complexation as well as for other ions d

158 the triazacyclononane-triphosphinate (TRAP) chelator, followed by automated (68)Ga labeling.

159 8, FBP10) or NOTA-monoamide (FBP9, FBP11) as chelators, followed by labeling with (64)Cu (FBP8 and FB

160 It is unclear how to tailor a chelator for Ac binding because Ac coordination chemistr

161 D-NN as a structurally new bifunctional HBED chelator for direct click coupling.

162 nstrate that tricine, considered a preferred chelator for studying the role of synaptic zinc, is unab

163 epidermal growth factor (HEGF), coupled to a chelator for subsequent radiolabelling with (111)Indium

164 ,7-triazonan-1-yl)pentanedioic acid (NODAGA) chelators for (68)Ga and (64)Cu labeling.

165 organic substances which can act as powerful chelators for dissolved iron and thus enhance its export

166 Unfortunately, progress in developing chelators for medicinal applications has been hindered b

167 ansporters, transcription factors, and metal chelators for metal uptake or exclusion.

168 ion-selective nanospheres as indicators and chelators for optical titrations.

169 Transporters responsible for Zn uptake and chelators for the internal transport of Zn were strictly

170 The aim of this study is to explore chelator-free labeling of LDH nanoparticles with radiois

171 e of magnetic field gradients; using a novel chelator-free method, the nanoparticles were radiolabele

172 d by light-triggered release of calcium or a chelator from liposomes.

173 rations and concentrations of the endogenous chelators haptoglobin, hemopexin, and alpha1- microglobu

174 This mitochondria-targeted iron chelator has therefore promising potential for skin phot

175 increased copper in tumors, and thus copper chelators have been used to inhibit tumor angiogenesis.

176 Macrocyclic chelators have been widely employed in the realm of nano

177 Iron chelators have been widely used to remove excess toxic i

178 Iron chelators have emerged as promising anticancer agents.

179 bitor Glu-NH-CO-NH-Lys(Ahx) using the (68)Ga chelator HBED-CC (PSMA(HBED)) allows imaging of prostate

180 Typically, such chelator heads are conjugated to either green or red flu

181 on-loaded nickel-nitrilotriacetic acid-based chelator heads conjugated to fluorophores, which is a co

182 y metal ion-loaded and fluorescently labeled chelator heads in PAGE and blot membranes.

183 s metal ion-loaded and fluorescently labeled chelator heads to detect His-tagged proteins in PAGE and

184 , by comparing the performances of different chelator heads, we show how differences in microscopic a

185 ulates biosynthesis of flagella and the iron chelator ICDH-Coumarin whose production requires the pvc

186 enteroids, administration of excess Cu or Cu chelators impaired assembly of chylomicrons.

187 -KO rendered hESCs more resistant to calcium chelator in blocking entry into naive state.

188 tol hexakisphosphate (IP6), is the main iron chelator in cereals and bread.

189 ey intermediate for CB-TE2A, a commonly used chelator in positron emission tomography medical imaging

190 jugating DFO reduces the cytotoxicity of the chelator in the macrophage cells.

191 our knowledge, the possibility of microbial chelator in the practical development of Al(3+) selectiv

192 were limited by REE affinity for the solvent chelator in the SLM, while the rates of REEs separation

193 s use of iron-binding chemistry of microbial chelators in order to functionalize the surface of iron

194 fferences among the currently available iron chelators, including pharmacokinetics, routes of adminis

195 clinical trials of AKI prevention using iron chelators, including selection of the ideal clinical set

196 Nicotianamine, a copper chelator, increased by 12-27 fold compared to the contro

197 bstitution experiments with synthetic Ca(2+) chelators indicated the presence of endogenous Ca(2+) bu

198 As thiosemicarbazone chelators induce stress and up-regulate NDRG1 to inhibit

199 Conversely, copper chelators inhibited phosphorylation of STAT3 and EGFR an

200 ma MCF-7 cells, we found that TEPA, a copper chelator, inhibited EMT-like cell morphology and cytoske

201 receptor-conserved Glu-283(VII:06/7.39) Both chelators interact with aromatic residues in the transme

202 dies in the search for an orally active iron chelator is thoroughly developed.

203 However, the antineoplastic activity of Cu chelators is cytostatic.

204 Cuprizone (CZ), a copper chelator, is widely used to study demyelination and remy

205 tic acid (BAPTA-AM), an intracellular Ca(2+) chelator known to deplete ER Ca(2+) stores.

206 for extracellular iron using strain-specific chelators known as siderophores.

207 ed ligand L(4a), two pyclen-based lanthanide chelators, L(4b) and L(4c), bearing two specific picolin

208 rney from O-donor through S-donor to N-donor chelator led to the development of a highly selective Au

209 The NOTA chelator ligand FAPI-74 can be labeled with both (18)F-A

210 argeted hexadentate (tricatechol-based) iron chelator linked to mitochondria-homing SS-like peptides.

211 (68)Ga-labeled chelator-linked FAP inhibitors (FAPIs) have been success

212 (gD) was radiolabeled with (89)Zr via 1 of 4 chelator-linker combinations (benzyl isothiocyanate-DFO

213 The pharmacokinetics associated with these 4 chelator-linker combinations were compared in 12 healthy

214 one uptake, and whole-body clearance between chelator-linker types, whereas little variation (+/-10%)

215 The iron chelator-loaded low-molecular-weight keratin hydrogel wi

216 Bifunctional HBED chelators make strong complexes with trivalent gallium a

217 anti-TfR1 is first labeled with a polymeric chelator (MAXPAR) with the subsequent incorporation of s

218 The solution to the problem, chelator-mediated iron removal, is clear.

219 nographene was observed, which revealed that chelator-mediated nanoparticle-based PET imaging has its

220 cane-1,4,7,10-tetraacetic acid) or DOTA-like chelator-modified peptide.

221 ide (NaCl)-based method for radiolabeling of chelator-modified peptides for molecular imaging.

222 hydrophilic amino acids were attached to the chelator moiety of the compound.

223 However, most gadolinium (Gd)-chelator MR contrast agents are limited by their relativ

224 inc concentration by treatment with the zinc chelator N,N,N'-tetrakis-(2'-pyridylmethyl)ethylenediami

225 caffold and utilize a variety of macrocyclic chelators, namely NOTA(3), PCTA(4), Oxo-DO3A(5), CB-TE2A

226 were expressed in hypnozoites and the copper chelator neocuproine was cidal to all liver stage parasi

227 f Arabidopsis unable to synthesize the metal chelator nicotianamine.

228 tide synthesis and elongated with respective chelators (NODA-GA, DOTA) for (68)Ga-labeling or proparg

229 HOPO has the potential to replace DFO as the chelator of choice for (89)Zr-based PET imaging agents.

230 Mimosine, a known chelator of Fe(III), may facilitate Fe(III) uptake in le

231 Nicotianamine (NA) is a natural chelator of Fe, zinc (Zn) and other metals in higher pla

232 es show that the ligand is a much more rapid chelator of Th(4+) than prevailing ligands (1,4,7,10-tet

233 ) carrying BBB-permeable neuropeptides and a chelator of the positron emitter (68)Ga as a PET reporte

234 Studies concerning the influence of chelators on biodistribution of (99m)Tc-labeled Affibody

235 Addition of an intracellular calcium chelator or an AMPK inhibitor to either mouse macrophage

236 Remarkably, when recruited via chelator or anionic lipids, respectively, the reengineer

237 Mice treated with a mitochondrial iron chelator or mice fed a low-iron diet were protected from

238 d CA3, as indicated by the ability of Zn(2+) chelators or Ca(2+) entry blockers to delay pyramidal ne

239 ved no more than 24 months of treatment with chelators or zinc, had a Leipzig score of 4 or more, and

240 The chelator p-SCN-Bn-DFO was conjugated to AMG102, radiolab

241 eruginosa and to treatment with a xenobiotic chelator, phenanthroline, in C. elegans.

242 e removed by disaggregation with the calcium-chelator phosphate buffer.

243 These findings identify the chelator phytate as an intracellular bacteriostatic comp

244 bactericide compounds by siderophores (iron chelators produced by bacteria) is a promising strategy

245 Siderophores are high-affinity iron chelators produced by microorganisms and frequently cont

246 ional negative charges (carboxylates) on the chelator, promoting renal clearance.

247 mice with deferiprone, a small molecule iron chelator, reduced oligodendrocyte apoptosis and enabled

248 Ammonium tetrathiomolybdate (ATTM), a copper chelator, releases sulfide in a controlled and novel man

249 Experiments with exogenous Ca(2+) chelators reveal that channel-sensor coupling at basket

250 her, studies using a membrane-permeable iron chelator, salicylaldehyde isonicotinoyl hydrazone, revea

251 r other radiometals that could use a similar chelator/scaffold combination for radiopharmaceutical th

252 Mycobactins are small-molecule iron chelators (siderophores) produced by Mycobacterium tuber

253 ral and unnatural hinduchelins are weak iron chelators (siderophores).

254 raction (WSF), rich in branched regions, and chelator soluble fraction (CSF), linear, with strong neg

255 OD5 indeed rapidly loses its copper to metal chelators such as EDTA, and binding constants for Cu(II)

256 ivation has stimulated the treatment with Zn chelators, such as diethyldithiocarbamate (DEDTC).

257 ween plant tissues is facilitated by organic chelators, such as nicotianamine and citrate.

258 nd ethylene glycol tetraacetic acid (calcium chelator) suggested existence of intermediate molecule(s

259 The CN + HP killing is blocked by iron chelators, suggesting Fenton's reaction.

260 the ability to grow in media containing iron chelators, suggesting the presence of additional pathway

261 the synthesis and secretion of high-affinity chelators termed siderophores.

262 Of the 17 iron chelators tested, six reduced cell viability of two NB c

263 Repurposing the clinical Cu chelator tetrathiomolybdate (TTM) is supported by effica

264 We conclude that ELT is a powerful iron chelator that decreases cellular iron and further enhanc

265 ry, a PTPmu-targeted peptide was linked to a chelator that had been conjugated to a lysine residue.

266 murine]) and can be obtained from the parent chelator that has low affinity.

267 d small molecule deferoxamine (DFO), an iron chelator that increases HIF-1alpha transactivation in di

268 FICANCE STATEMENT Cuprizone (CZ) is a copper chelator that induces demyelination.

269 eatment of disease-is identifying an (225)Ac chelator that is compatible with in vivo applications.

270 molecule by conjugation of BIST to a Ca(2+) chelator that upon laser flash photolysis rapidly releas

271 reduce iron accumulation is the use of iron chelators that are able to cross the blood-brain barrier

272 e thiosemicarbazone (TSC) class of metal ion chelators that bind iron, copper, magnesium, zinc, and o

273 Quinolinols are known chelators that can disrupt the BoNT/A metalloprotease zi

274 the active secretion of protons and organic chelators that enhance calcium dissolution at fungal-min

275 hnetium complexes with tetradentate tripodal chelator (the tris(2-mercaptoethyl)amine (NS3)) and the

276 radiometal-based radiopharmaceutical is the chelator, the ligand system that binds the radiometal io

277 mbined iontophoretic application of a Ca(2+) chelator to selectively disrupt the tip links of individ

278 have been the difficulty in finding suitable chelators to stably attach it to targeting vehicles such

279 The successful search for orally active iron chelators to treat transfusional iron-overload diseases,

280 -uptake of siderophores, small molecule iron chelators, to scavenge iron.

281 ainly chronic anemia, iron overload and iron chelator toxicity.

282 On the basis of the (68)Ga chelators TRAP (triazacyclononane-triphosphinate) and NO

283 Methods: On the basis of the (68)Ga chelators TRAP (triazacyclononane-triphosphinate) and NO

284 reduction of copper with the clinical copper chelator TTM inhibits MEK1/2 kinase activity and reduces

285 Additionally, the chelator used in this compound allows labeling with the

286 asirox and deferiprone are the only two oral chelators used in adult patients with transfusion-depend

287 paration of (99m)Tc-tricarbonyl complexes, a chelator was selected whose carboxylic acids can easily

288 tazolamide, a spacer, and a peptidic (99m)Tc chelator, was labeled using sodium pertechnetate under r

289 The new generation chelators were conjugated to Tyr3-octreotate (Y3-TATE) t

290 lone-based FAP inhibitors (FAPIs) coupled to chelators were developed displaying specific binding to

291 ylmethyl) ethylenediamine, a specific Zn(2+) chelator, whereas nontumorigenic esophageal epithelial c

292 loring the relative configuration of dye and chelator, which can be targeted using the HaloTag self-l

293 ational states, rather than active site iron chelators, which make up most reported 2OG oxygenase inh

294 h a thiol-reactive fluorescent dye and via a chelator with a radionuclide.

295 -2, a recently developed high affinity Cu(I) chelator with low zeptomolar dissociation constant, we u

296 conjugate of a tris(hydroxypyridinone) (THP) chelator with the established urea-based PSMA inhibitor

297 The employed approach uses a bifunctional chelator with two Abeta-interacting fragments that drama

298 host or other bacteria through specific iron chelators with high binding affinity.

299 novel tracers that combine dedicated copper chelators with the PSMA-specific urea-based binding moti

300 comparing deferiprone, a less expensive iron chelator, with deferasirox in paediatric patients.